Enveric Biosciences, Inc.
ENVB
$5.32
$0.224.31%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -16.08% | 19.70% | -2.34% | -27.88% | 209.65% |
| Depreciation & Amortization | -52.12% | -52.36% | -52.83% | -5.15% | -2.60% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -30.87% | -10.05% | 32.73% | -11.70% | 33.11% |
| Operating Income | 30.87% | 10.05% | -32.73% | 11.70% | -33.11% |
| Income Before Tax | 30.29% | 10.09% | -34.04% | 11.01% | 7.80% |
| Income Tax Expenses | -- | -- | -- | -- | -67.71% |
| Earnings from Continuing Operations | 30.44% | 10.09% | -34.04% | 11.07% | 8.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 30.44% | 10.09% | -34.04% | 11.07% | 8.19% |
| EBIT | 30.87% | 10.05% | -32.73% | 11.70% | -33.11% |
| EBITDA | 30.31% | 8.25% | -36.73% | 11.93% | -34.42% |
| EPS Basic | 89.37% | 74.91% | 73.88% | 86.80% | 78.72% |
| Normalized Basic EPS | 94.21% | 86.12% | 73.88% | 86.79% | 78.63% |
| EPS Diluted | 89.37% | 74.91% | 73.88% | 86.80% | 78.72% |
| Normalized Diluted EPS | 94.21% | 86.12% | 73.88% | 86.79% | 78.63% |
| Average Basic Shares Outstanding | 1,103.83% | 547.11% | 412.56% | 574.77% | 331.50% |
| Average Diluted Shares Outstanding | 1,103.83% | 547.11% | 412.56% | 574.77% | 331.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |